<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:department>College of Life Sciences</gtr:department><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/CDD174FB-3B27-4CCD-A3DF-D330F6EEBA68"><gtr:id>CDD174FB-3B27-4CCD-A3DF-D330F6EEBA68</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:surname>Keatch</gtr:surname><gtr:orcidId>0000-0002-2109-8305</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D8E3C4C0-9FF8-4D15-95B6-3B4D435B1870"><gtr:id>D8E3C4C0-9FF8-4D15-95B6-3B4D435B1870</gtr:id><gtr:firstName>Keith</gtr:firstName><gtr:surname>Baar</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FE008925%2F1"><gtr:id>5F00A138-572A-423F-8A40-5AB346E02FE6</gtr:id><gtr:title>Using drugs, machines, and genes to engineer functional muscle</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/E008925/1</gtr:grantReference><gtr:abstractText>The goal of tissue engineering is to use scaffolding materials and multipotent stem cells to produce tissue replacements. In engineering muscle, this is made more complex by the fact that the function of muscle is to produce force and therefore the scaffold has to be compliant and biodegradable. While great progress has been made towards this goal, a number of obstacles remain, including: 1) vascularization of the engineered muscle; 2) creation of effective interfaces between muscle and bone/artificial materials; 3) maturation of the muscle, since it is developmentally arrested; and 4) the development of normal muscle fibre size and strength. The result is that the current state-of-the-art tissue engineered muscles are 0.2mm thick and produce at best 35% of the relative force of a neonatal muscle. In order to make the engineered muscles bigger and increase their force production, we propose to use drugs to remove inhibitors of muscle growth and development, machines to stretch and electrically stimulate muscle growth and development, and genes to increase muscle fibre size and therefore force production. The research combines discoveries made in vivo studying muscle physiology with our engineered muscle model to try to make bigger, stronger and more adult muscle in culture.</gtr:abstractText><gtr:fund><gtr:end>2009-10-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2007-04-30</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>217658</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AF511759-3F3F-49F4-A23F-56CE524A6053</gtr:id><gtr:title>Factors affecting the longevity and strength in an in vitro model of the bone-ligament interface.</gtr:title><gtr:parentPublicationTitle>Annals of biomedical engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a1fe2897654ee0475be93e198f4dd8c"><gtr:id>1a1fe2897654ee0475be93e198f4dd8c</gtr:id><gtr:otherNames>Paxton JZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0090-6964</gtr:issn><gtr:outcomeId>5461fea5332e57.28965883</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>296CF963-E7B2-49CE-B312-39EE54CD59AF</gtr:id><gtr:title>Biomaterials in regenerative medicine: engineering to recapitulate the natural.</gtr:title><gtr:parentPublicationTitle>Current opinion in biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbe0441d7faedc475bcbb28f44580084"><gtr:id>cbe0441d7faedc475bcbb28f44580084</gtr:id><gtr:otherNames>Keatch RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0958-1669</gtr:issn><gtr:outcomeId>5461fd0b2744d0.72143292</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0F6AF33-7373-4E7D-8B10-FEBD500C5C5B</gtr:id><gtr:title>Pyruvate suppresses PGC1alpha expression and substrate utilization despite increased respiratory chain content in C2C12 myotubes.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Cell physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cfb27e6197d72c31a716d2930789458"><gtr:id>7cfb27e6197d72c31a716d2930789458</gtr:id><gtr:otherNames>Philp A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0363-6143</gtr:issn><gtr:outcomeId>5a351b3eed3d41.58679289</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D32C6EB-8040-42E5-95F2-F272430B8827</gtr:id><gtr:title>The PGC-1a-related coactivator promotes mitochondrial and myogenic adaptations in C2C12 myotubes.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Regulatory, integrative and comparative physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7cfb27e6197d72c31a716d2930789458"><gtr:id>7cfb27e6197d72c31a716d2930789458</gtr:id><gtr:otherNames>Philp A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0363-6119</gtr:issn><gtr:outcomeId>5a351c1308f5c9.93373502</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7823683E-FB40-402C-91AB-4D052523A969</gtr:id><gtr:title>Optimizing an intermittent stretch paradigm using ERK1/2 phosphorylation results in increased collagen synthesis in engineered ligaments.</gtr:title><gtr:parentPublicationTitle>Tissue engineering. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a1fe2897654ee0475be93e198f4dd8c"><gtr:id>1a1fe2897654ee0475be93e198f4dd8c</gtr:id><gtr:otherNames>Paxton JZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1937-3341</gtr:issn><gtr:outcomeId>5a351c5d973b30.16757614</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D305DC89-7D59-4BFA-B216-4AC09A464C17</gtr:id><gtr:title>A novel bioreactor for stimulating skeletal muscle in vitro.</gtr:title><gtr:parentPublicationTitle>Tissue engineering. Part C, Methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcbb40b03d03aae231a271a8064ebf07"><gtr:id>dcbb40b03d03aae231a271a8064ebf07</gtr:id><gtr:otherNames>Donnelly K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1937-3384</gtr:issn><gtr:outcomeId>5a351ca5157440.12749051</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>046AAA2A-3B28-441E-BECF-94FF6810EE10</gtr:id><gtr:title>Engineering the bone-ligament interface using polyethylene glycol diacrylate incorporated with hydroxyapatite.</gtr:title><gtr:parentPublicationTitle>Tissue engineering. Part A</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a1fe2897654ee0475be93e198f4dd8c"><gtr:id>1a1fe2897654ee0475be93e198f4dd8c</gtr:id><gtr:otherNames>Paxton JZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1937-3341</gtr:issn><gtr:outcomeId>5461fea50e9604.38478532</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46D9B7DB-E4D6-4A3B-AB4A-41BC1E7DFFFE</gtr:id><gtr:title>Absence of the Birt-Hogg-Dub&amp;eacute; gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7792171575859b9ac964c0af62e71cb9"><gtr:id>7792171575859b9ac964c0af62e71cb9</gtr:id><gtr:otherNames>Preston RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>56758e569932a</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/E008925/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>6723A70B-A523-40AB-9740-B6AD2A0677B7</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Medical &amp; health interface</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>195B48B4-2BC5-4DEB-BA1A-323A90D8730D</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Tissue engineering</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>